[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"optic-nerve-diseases\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:optic-nerve-diseases":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,75,101,121],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100411197","a-phase-i-feasibility-study-of-an-intracortical-visual-prosthesis-icvp-for-people-with-blindness-100411197",false,"NCT04634383","A Phase I Feasibility Study of an Intracortical Visual Prosthesis (ICVP) for People With Blindness","ICVP - A Phase I Clinical Trial to Determine the Feasibility of a Human Cortical Visual Prosthesis for People With Blindness","ICVP","Inclusion Criteria:\n\n* No light perception or bare light perception, in each eye in accordance with relevant International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes, where the physician has no expectation of improvement through currently approved treatments.\n* History of normal or near-normal vision, with or without refractive correction, during at least the first 10 years of life.\n* Adjusted to blindness for at least one year.\n* History of vision or blindness rehabilitation.\n* Willing and able to meet the time demands of the study with transportation assistance.\n* Willing to agree to audio and video recording, as specified in the pre-screening consent.\n* Motivated by altruism, willingness to participate in pioneering science.\n* Demonstrated support from spouse, family and\u002For friends.\n* High or average cognitive and spatial functioning.\n* Normal structural MRI.\n* English as preferred language.\n* Normal decision-making capacity.\n\nExclusion Criteria:\n\n* Poor adjustment to blindness, or vision loss within the last year.\n* Expectation of vision restoration to pre-blindness level through trial participation.\n* History of alcohol or drug dependence.\n* Evidence of prior immune response to an orthopedic implant which caused the implant to be explanted\n* A disease prognosis of living less than five years.\n* An implant which would prevent screening using MRI, or a pacemaker, or similar implant.\n* A history of seizures.\n* Current suicidal ideation.\n* Poor decision-making capacity.\n* Current diagnosis or history of severe mental illness.\n* Women who are pregnant or plan on becoming pregnant in the duration of the trial.\n* Hand Motion (HM) vision or better vision,\n* No Light Perception (NLP) or Light Perception (LP) vision with present OptoKinetic Nystagmus (OKN)\n* NLP vision with pupil constriction\n* Patients with Islands of perceivable vision in Goldmann Visual Field or Confrontational visual Field will also be excluded from the study.\n* Patients with Complete media opacity (complete cornea opacity, very dense cataract) that does not allow visualization of the posterior segment to determine the cause of blindness will be excluded from the study. Only patients with NLP and LP vision without OKN will be included in the study.\n* Patients with NLP or LP vision since birth will also be excluded from the study, as they may not have fully developed higher visual pathways, including cortical connections","ALL","19 Years","70 Years",{"count":5,"type":21},"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to determine the feasibility of producing artificial vision in persons with blindness. Study participants will have wireless electrical stimulators implanted into the cortical vision processing areas of their brains. The ability of the participants to perceive artificial vision in response to electrical stimulation will be assessed.",[27,28,29,30],"Ocular Injury","Optic Nerve Diseases","Photoreceptor Degeneration","Blindness,Acquired",[32,33,34],"Blindness","Visual Prosthesis","Electrical Stimulation","RECRUITING","2026-06-01",{"date":38,"type":39},"2026-06-03","ACTUAL",{"date":41,"type":39},"2020-08-20",{"date":43,"type":21},"2027-06-30",{"name":45,"class":46},"Illinois Institute of Technology","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":47},"100632040","early-temporal-dynamics-of-optic-nerve-sheath-diameter-after-therapy-in-gca-100632040","NCT07508514","Early Temporal Dynamics of Optic Nerve Sheath Diameter After Therapy in GCA","Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis","SONIC-TIME","Inclusion Criteria:\n\n1. Participants must be enrolled in SONIC-GCA and must have:\n\n   * completed the baseline optic nerve sheath ultrasound\n   * confirmed GCA as determined by the baseline standardized GCA assessment in SONIC-GCA.\n2. Exposure to glucocorticoids for ≤ 48 hours and ≤ 160 mg prednisone-equivalent before baseline.\n3. Ability and willingness to provide written informed consent.\n4. Agreement to complete the SONIC-TIME intensive follow-up schedule.\n\nExclusion Criteria:\n\n1\\) Concurrent participation in a blinded interventional pharmaceutical clinical trial.","50 Years",{"count":58,"type":21},60,"OBSERVATIONAL","Giant cell arteritis (GCA) is an inflammatory disease of large and medium arteries that can cause irreversible vision loss. Glucocorticoids (GCs) rapidly suppress inflammation, but diagnostic imaging tests such as temporal artery ultrasound or biopsy often become falsely negative within days of treatment. The optic nerve sheath diameter (ONSD), measurable by ocular ultrasound, reflects perineural edema and may serve as a quantitative biomarker of ocular inflammation in GCA.\n\nThe SONIC-TIME study (Early Temporal Dynamics of Optic Nerve Sheath Diameter After Glucocorticoid Therapy in Giant Cell Arteritis) is a single-center, prospective observational substudy embedded within SONIC-GCA (NCT05749094) at Hôpital du Sacré-Cœur de Montréal. It aims to characterize how rapidly ONSD decreases after GC initiation and how this trajectory relates to cumulative GC exposure, intravenous methylprednisolone, and early use of steroid-sparing therapies.\n\nSixty participants with newly diagnosed GCA will undergo serial optic nerve sheath ultrasound, blood tests (CRP, ESR), and when feasible, temporal artery ultrasound over the first two months of therapy (Days 3, 7, 10, 14, 21, 28, and Month 2). No experimental treatments are given; all participants receive standard-of-care therapy.\n\nThe primary objective is to quantify the percent change in mean ONSD from baseline to Day 28. Secondary objectives include modeling ONSD change over time, assessing associations with cumulative steroid dose and inflammatory markers, and estimating the time to normalization below the SONIC-GCA cutoff. Findings will define the optimal imaging window and refine the diagnostic and monitoring role of optic nerve ultrasound in GCA.",[62,63,28,64],"Giant Cell Arteritis","Temporal Arteritis","Diagnosis","NOT_YET_RECRUITING","2026-03-31",{"date":68,"type":39},"2026-04-02",{"date":70,"type":21},"2026-05-01",{"date":72,"type":21},"2028-05-01",{"name":74,"class":46},"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":81,"sex":17,"minAge":82,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":97,"leadSponsor":99,"locationsCount":47},"100580766","advancing-pediatric-retinal-imaging-with-auto-aligned-oct-100580766","NCT06841575","Advancing Pediatric Retinal Imaging With Auto-aligned OCT","Inclusion Criteria:\n\n* Group 1: Healthy adult volunteers\n* Subject is able and willing to consent to study participation\n* Subject is more than 18 years of age\n* Healthy adult volunteers without known ocular issues other than refractive error\n* Group 2: Adult patients in ophthalmology clinics\n* Health care provider, knowledgeable of protocol, agrees that study personnel could contact the subject\n* Subject is able and willing to consent to study participation\n* Subject is more than 18 years of age and is a patient in the Duke Eye Center ophthalmology clinics\n* Group 3: Pediatric participants in ophthalmology clinics\n* Health care provider, knowledgeable of protocol, agrees that study personnel could contact the parent\u002Flegal guardian\n* Parent\u002Flegal guardian is able and willing to consent to study participation\n* Pediatric patient less than 18 years of age in Duke Eye Center ophthalmology clinics or undergoing clinically-indicated examination under anesthesia at Duke Eye Center\n\nExclusion Criteria:\n\n* Group 1: Healthy adult volunteers\n* Students or employees under direct supervision of the investigators\n* Subjects with prior problems with pupil dilation\n* Pregnant woman if receiving dilating drops\n* Group 2: Adult patients in ophthalmology clinics\n* Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)\n* Group 3: Pediatric participants in ophthalmology clinics\n* Parent\u002Flegal guardian unwilling or unable to provide consent\n* Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)",true,"1 Month",{"count":84,"type":21},50,[24],"The goal of the current study is to conduct a pilot study to test a new version of the handheld OCT device capable of auto-alignment to image the retina in adult volunteers, and adult and pediatric patients in clinic.",[88,89,90,28],"Eye Diseases","Retinal Disease","Glaucoma",[92],"Optical Coherence Tomography (OCT)","2026-03-23",{"date":95,"type":39},"2026-03-25",{"date":93,"type":39},{"date":98,"type":21},"2027-09",{"name":100,"class":46},"Duke University",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":81,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":108,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":110,"conditions":111,"keywords":112,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":47},"100526805","optimize-pediatric-oct-imaging-100526805","NCT06139523","Optimize Pediatric OCT Imaging","Optimize Pediatric OCT (Optical Coherence Tomography) Imaging: a Pilot Study","Inclusion Criteria:\n\n* Group 1 - Healthy adult volunteers\n* Subject is able and willing to consent to study participation\n* Subject is more than 18 years of age\n* Healthy adult volunteers without known ocular issues other than refractive error\n* Pregnancy Reasonably Excluded Guide (PREG) evaluation on women of childbearing potential\n* Group 2 - Pediatric participants\n* Health care provider, knowledgeable of protocol, agrees that study personnel could contact the parent\u002Flegal guardian\n* Parent\u002Flegal guardian is able and willing to consent to study participation\n* Pediatric patient less than 18 years of age in Duke Eye Center ophthalmology clinics or undergoing clinically-indicated examination under anesthesia at Duke Eye Center\n\nExclusion Criteria:\n\n* Group 1 - Healthy adult volunteers\n* Students or employees under direct supervision of the investigators\n* Subjects with prior problems with pupil dilation\n* Pregnant woman if receiving dilating drops\n* Group 2 - Pediatric participants\n* Parent\u002Flegal guardian unwilling or unable to provide consent\n* Participant has a health or eye condition that preclude eye examination or retinal imaging (such as corneal opacity or cataract)",{"count":109,"type":21},30,"Handheld optical coherence tomography (OCT) has become an important imaging modality to evaluate the pediatric retina. The objective of this pilot study is to compare a new contact OCT system (Theia Imaging) with an investigational noncontact OCT system (Duke Biomedical Engineering) to assess their ability to image the pediatric retina.\n\nThe investigators hypothesize that the contact OCT system is superior in imaging larger areas of the retina (larger field-of-view), while it has similar resolution to image the retina substructures (non-inferior image quality).",[89,90,28],[92],"2025-09-16",{"date":115,"type":39},"2025-09-17",{"date":117,"type":39},"2024-01-24",{"date":119,"type":21},"2026-12",{"name":100,"class":46},{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":127,"eligibilityCriteria":128,"healthyVolunteers":11,"sex":17,"minAge":129,"maxAge":4,"enrollmentInfo":130,"targetDuration":4,"studyType":22,"phases":132,"briefSummary":133,"conditions":134,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":47},"100487387","electrical-stimulation-for-the-treatment-of-optic-neuropathies-100487387","NCT05626426","Electrical Stimulation for the Treatment of Optic Neuropathies","An Open-Label Study to Evaluate the Safety and Efficacy of Repetitive, Transorbital Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies","rtACS","Inclusion Criteria:\n\n1. Participant must be at least 18.\n2. Participant must has the ability to comply with the requirements of the study and complete the schedule of events (SOE).\n3. Participant's clinical diagnosis must be consistent with glaucoma characterized by the following features: Mean deviation (MD) worse than -3 on Humphrey Visual Field 24-2 testing. Reliable visual field measures, fixation losses do not exceed 20% and false postivies do not exeed 20%.\n4. In the opinion of the investigator the participant's eye pressure must be clinically stable.\n5. If a participant has two eyes meeting study criteria, the worse eye as determined by mean deviation. If both eyes qualify and have the same MD, the patient may choose which eye they are willing to enter, or else a randomization procedure will assign one eye to the study.\n6. Participant must understand and sign the informed consent. If the participant's vision is impaired to the point where he\u002Fshe cannot read the informed consent document, the document will be read to the participant in its entirety.\n\nExclusion Criteria:\n\n1. Participant is unable to comply with study procedures or follow-up visits.\n2. Participant has a history of ocular herpes zoster.\n3. Participant has pathological nystagmus\n4. Participant has evidence of visually significant retinopathy including but not limited to Diabetic retinopathy or retinitis pigmentosa.\n5. Participant has evidence of corneal opacification or lack of optical clarity.\n6. Participant has uveitis or other ocular inflammatory disease.\n7. Participant has any electric or electroinc implants such as a pacemaker.\n8. Participant has acute conjunctivitis.\n9. Participant has acute autoimmune disease.\n10. Participant is pregnant or lactating.\n11. Participant has, in the opinion of the investigator, any physical or mental condition that would increase the risk of participation in the study or may interfere with the study procedures, evaluations and outcome assessments. Including but not limited to all forms of dementia.\n12. Unresected brain tumors\n13. Implanted intracranial magnetic metals (metallic implants in the head \u002F skull such as clamps, coils, ventriculo-peritoneal shunts, endoprostheses, etc.), which are not MRI-compatible. Note: metallic dental implants and titanium screws or plates are acceptable\n14. Patients with any skin damage.\n15. Children and comatose patients.\n16. Patients with history of epileptic seizure within the last 10 years.\n17. Patients with uncontrolled systemic hypertension or uncontrolled diabetes.\n18. Participant is not able to travel, to comply with the requirements of the study or not willing to complete the schedule of events (SOE) and\u002For unable to confirm follow-up participation\n19. Prior participation in a vision training\u002Fstimulation study in the last 12 months","18 Years",{"count":131,"type":21},40,[24],"The overall aim of this study is to see whether long-term electrical stimulation with a home-stimulation device works well and is safe for the treatment of open-angle glaucoma. Open-Angle Glaucoma is a disease where the nerves in the back of your eye die off faster than expected regardless of your eye pressure.",[90,135,28],"Glaucoma, Open-Angle","2025-07-02",{"date":138,"type":39},"2025-07-08",{"date":140,"type":39},"2023-02-27",{"date":142,"type":21},"2027-12",{"name":144,"class":46},"Stanford University"]